Also found in: Medical.
ADAS-cogAlzheimer’s Disease Assessment Scale Cognitive Subscale
References in periodicals archive ?
The research was presented at the 8th Clinical Trials On Alzheimer's Disease meeting in Barcelona, Spain, in a poster titled "The Impact of Electronic Administration of the ADAS-Cog, MMSE and CDR-SB on Clinical Trial Data Quality.
Modifications of the MMSE and ADAS-Cog scores after 12 months of follow-up were considered as cognitive outcome variables of interest.
These results reproduce those that the investigators obtained in a previous psychometric evaluation of the ADAS-Cog in patients who participated in a randomized, controlled clinical trial (J.
1 points higher than patients on placebo, when measured by the ADAS-Cog Scale.
ADAS-cog puani, FATT ve SMMT sonuclarinin hastalik suresi, kranyal plak sayisi ve EDSS ile iliskisini arastirmak icin yapilan korelasyon degerlendirmesinde istatistiksel olarak anlamli bir iliski saptanmamistir (p>0.
Numerous clinical studies have demonstrated that modest improvements in ADAS-cog scores - on the order of 2 to 3 points over the course of a year - have been associated with significant cost reductions in overall managed care expenditures.
Although the vitamin supplement regimen was effective in reducing homocysteine levels, it had no beneficial effect on the primary cognitive measure, rate of change in ADAS-cog score during 18 months or on any secondary measures.
Comparing mean pre-post differences in ADAS-cog total scores separately for drug and placebo groups, the contributions of changes upon drug and placebo treatment, respectively, to the total drug-placebo difference at the end of treatment were assessed.
Improvement in cognitive function and functional capacity was seen in the masitinib treatment group when compared to a placebo group, as evident through the sustained and statistically significant response in ADAS-Cog, as well as the mean change in ADAS-Cog, MMSE, and ADCS-ADL values relative to baseline.
The MINDSET trial is designed to confirm the results of a 684-patient international, multi-center, double-blind placebo-controlled study in which patients on a stable background of donepezil therapy receiving 35 mg RVT-101 demonstrated statistically significant improvements on the ADAS-cog and ADCS-ADL as compared to patients receiving donepezil alone.
However, the most recent trial failed to show any statistically significant or clinically meaningful changes in any of the three outcomes it assessed: ADAS-cog, ADAS-activities of daily living (ADAS-ADL), or the Clinical Dementia Rating-sum of boxes (CDR-sb).